Drugs to Increase Insulin Sensitivity
Metformin and thiazolidinediones (pioglitazone or rosiglitazone) are the primary pharmacologic agents that directly increase insulin sensitivity in patients with type 2 diabetes. 1, 2, 3
Primary Insulin Sensitizers
Metformin (First-Line Agent)
Metformin should be the initial pharmacologic choice for most patients with type 2 diabetes as it enhances primarily hepatic and muscle insulin sensitivity without directly affecting β-cell function 4, 2, 3. The drug decreases hepatic glucose output and improves peripheral insulin sensitivity, making it a true insulin sensitizer 1.
Key characteristics of metformin:
- Weight neutral or promotes modest weight loss 4, 2
- Low risk of hypoglycemia when used as monotherapy 4, 3
- May reduce cardiovascular events 4, 3
- Inexpensive and has long-standing safety data 4, 3
Contraindications and precautions:
- Do not use if eGFR <30 mL/min/1.73 m² 2
- Do not initiate if eGFR <45 mL/min/1.73 m² 2
- Reduce dose if eGFR 30-45 mL/min/1.73 m² 2
- Monitor vitamin B12 levels periodically due to risk of deficiency 2, 3
- Common gastrointestinal side effects (nausea, diarrhea, dyspepsia) 2
Thiazolidinediones (TZDs)
Thiazolidinediones (pioglitazone and rosiglitazone) are potent insulin sensitizers that improve peripheral insulin sensitivity and can preserve or improve β-cell function 2, 3. These agents work through PPARγ activation, fundamentally addressing the pathophysiology of insulin resistance 1.
Pioglitazone specifically has demonstrated cardiovascular benefits in high-risk patients with type 2 diabetes, with statistically significant reductions in the composite outcome of nonfatal MI, stroke, and all-cause mortality 2, 5. This makes pioglitazone particularly valuable when both insulin sensitization and cardiovascular protection are needed.
Important considerations for TZDs:
- High glucose-lowering efficacy 4, 3
- Cause weight gain (comparable to sulfonylureas and insulin) 2, 3
- Risk of fluid retention, particularly in patients with cardiac or renal disease 2
- Associated with edema, heart failure risk, and bone fractures 4
- High cost compared to metformin 4
- May benefit patients with NASH 2
Clinical evidence shows TZDs improve both insulin resistance (HOMA-R) and β-cell function (HOMA-B) 6. The ADOPT trial demonstrated that rosiglitazone provided superior durability of glycemic control compared with metformin and glyburide, with more favorable changes in β-cell function and insulin sensitivity over 4 years 6.
Clinical Algorithm for Insulin Sensitizer Selection
Step 1: Start with metformin unless contraindicated (renal impairment, intolerance) 4, 2
Step 2: If additional insulin sensitization is needed or metformin is contraindicated:
- Consider adding a TZD (pioglitazone preferred if cardiovascular disease present) 2, 5
- Caution: Avoid TZDs in patients with heart failure, significant fluid retention risk, or osteoporosis 2, 3
Step 3: Continue metformin as long as tolerated even when adding other agents 2
Important Caveats
While GLP-1 receptor agonists and SGLT2 inhibitors have become preferred add-on agents due to cardiovascular and renal benefits 2, 7, they do not primarily work through insulin sensitization mechanisms. GLP-1 RAs stimulate insulin secretion in a glucose-dependent manner and promote satiety 3, while SGLT2 inhibitors work through renal glucose excretion 3.
DPP-4 inhibitors, sulfonylureas, and meglitinides primarily enhance insulin secretion rather than insulin sensitivity 4, 1, 3. These are not insulin sensitizers despite being effective glucose-lowering agents.
For patients with metabolic syndrome, PCOS, or significant insulin resistance, metformin remains the first choice, with TZDs as a second-line option when additional insulin sensitization is specifically needed 1, 8, 1. The combination of metformin plus a TZD provides dual insulin-sensitizing mechanisms targeting both hepatic and peripheral insulin resistance 1, 9.